InvestorsHub Logo

Edward

11/16/15 8:13 AM

#96196 RE: Myth #96195

Myth, concerned about this statement though:

However, at the end of the third quarter a large tissue customer informed the Company that they expect a significant reduction in orders such that orders from this customer will be minimal in the foreseeable future. This reduction commenced in October. Year-to-date through the third quarter, this customer represented approximately 12% of our total gross profit. Operating expenses related to the tissue business are disproportionately lower than our cord blood and cord tissue processing and storage business. The Company should continue to generate positive EBITDA and cash flow in the fourth quarter and in 2016 inclusive of diligently managing expenses."

Myth

11/16/15 8:38 AM

#96200 RE: Myth #96195

Sept 30, 2015

Cash - $ 776,782


Up from 708,146 Q2.....